{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Enteropathy-Associated+T-Cell+Lymphoma&page=2",
    "query": {
      "condition": "Enteropathy-Associated T-Cell Lymphoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Enteropathy-Associated+T-Cell+Lymphoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T14:52:35.320Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03049449",
      "title": "T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Large-Cell, Anaplastic",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Extranodal NK-T-Cell",
        "Lymphoma, T-Cell, Peripheral"
      ],
      "interventions": [
        {
          "name": "Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "18 Years to 73 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-03-17",
      "completion_date": "2022-01-26",
      "has_results": true,
      "last_update_posted_date": "2023-01-18",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049449"
    },
    {
      "nct_id": "NCT02652715",
      "title": "Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Adult T-Cell Leukemia/Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-Cell Lymphoma",
        "B Lymphoblastic Leukemia/Lymphoma",
        "Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Burkitt Leukemia",
        "Central Nervous System Lymphoma",
        "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3 Follicular Lymphoma",
        "Hepatosplenic T-Cell Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle Cell Lymphoma",
        "Mediastinal (Thymic) Large B-Cell Lymphoma",
        "Mycosis Fungoides",
        "Nasal Type Extranodal NK/T-Cell Lymphoma",
        "Nodal Marginal Zone Lymphoma",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
        "Post-Transplant Lymphoproliferative Disorder",
        "Primary Cutaneous Anaplastic Large Cell Lymphoma",
        "Primary Effusion Lymphoma",
        "Sezary Syndrome",
        "Splenic Marginal Zone Lymphoma",
        "Subcutaneous Panniculitis-Like T-Cell Lymphoma",
        "Systemic Anaplastic Large Cell Lymphoma",
        "T Lymphoblastic Leukemia/Lymphoma",
        "Transformed Recurrent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Salvia hispanica Seed",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2016-01-19",
      "completion_date": "2019-11-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02652715"
    },
    {
      "nct_id": "NCT00002520",
      "title": "Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Lung Cancer",
        "Lymphoma",
        "Prostate Cancer",
        "Testicular Germ Cell Tumor",
        "Tobacco Use Disorder",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "nicotine",
          "type": "DRUG"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "19 Years to 120 Years"
      },
      "enrollment_count": 434,
      "start_date": "1990-12-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002520"
    },
    {
      "nct_id": "NCT02588651",
      "title": "A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Hepato-splenic T-cell Lymphoma",
        "Adult T-cell Leukemia/Lymphoma",
        "Enteropathy Associated T-cell Lymphoma",
        "NK T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Deepa Jagadeesh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2016-06-17",
      "completion_date": "2024-10-14",
      "has_results": true,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 4,
      "location_summary": "Detroit, Michigan • Hackensack, New Jersey • Cleveland, Ohio",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02588651"
    },
    {
      "nct_id": "NCT04803201",
      "title": "Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Angioimmunoblastic T-cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Follicular T-Cell Lymphoma",
        "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma",
        "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype",
        "Peripheral T-Cell Lymphoma, Not Otherwise Specified"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Duvelisib",
          "type": "DRUG"
        },
        {
          "name": "Oral azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2021-10-08",
      "completion_date": "2027-05-19",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 89,
      "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 69 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04803201"
    },
    {
      "nct_id": "NCT00073944",
      "title": "BCX-1777 in Treating Patients With Refractory Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "forodesine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00073944"
    },
    {
      "nct_id": "NCT05475925",
      "title": "A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "LGLL - Large Granular Lymphocytic Leukemia",
        "Primary Cutaneous Gamma-Delta T-Cell Lymphoma",
        "Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma",
        "Hepatosplenic T-cell Lymphoma",
        "Subcutaneous Panniculitis-Like T-Cell Lymphoma",
        "Aggressive NK Cell Leukemia",
        "Systemic EBV1 T-cell Lymphoma, if CD8 Positive",
        "Hydroa Vacciniforme-Like Lymphoproliferative Disorder",
        "Extranodal NK/T Cell Lymphoma, Nasal Type",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma",
        "Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)",
        "Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)"
      ],
      "interventions": [
        {
          "name": "DR-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dren Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2022-07-13",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Duarte, California • Irvine, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05475925"
    },
    {
      "nct_id": "NCT00787527",
      "title": "SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zolinza (vorinostat)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2008-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-09-09",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787527"
    },
    {
      "nct_id": "NCT07388563",
      "title": "Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, T Cell, Peripheral",
        "T-cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Monomorphic Epitheliotropic Intestinal T-cell Lymphoma",
        "Adult T-cell Leukemia/Lymphoma"
      ],
      "interventions": [
        {
          "name": "azacitidine",
          "type": "DRUG"
        },
        {
          "name": "abatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-03-26",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07388563"
    },
    {
      "nct_id": "NCT05377827",
      "title": "Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-Cell Non-Hodgkin Lymphoma",
        "Acute Myeloid Leukemia",
        "Angioimmunoblastic T-cell Lymphoma",
        "Enteropathy-Associated T-Cell Lymphoma",
        "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma",
        "Peripheral T Cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Adult T Cell Leukemia",
        "Adult T Cell Lymphoma",
        "T Cell Prolymphocytic Leukemia",
        "Extranodal NK/T-cell Lymphoma",
        "Transformed Mycosis Fungoides",
        "Sezary Syndrome",
        "Primary Cutaneous Gamma-Delta T-Cell Lymphoma",
        "Hepatosplenic T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "WU-CART-007",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-10-10",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-06-10T14:52:35.320Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377827"
    }
  ]
}